Meghan Nicole Miller

Ms. Meghan Nicole Miller

David Geffen School of Medicine at UCLA, Los Angeles, California, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JCJustin Choi
Justin Choi
ZBZachary Bordeaux
Zachary Bordeaux
JMJaimie McKeel
Jaimie McKeel
CNCory Nanni
Cory Nanni
NSNishadh Sutaria
Nishadh Sutaria
MKMadan Kwatra
Madan Kwatra
Epidermal Growth Factor Receptor (EGFR) is amplified in over 50% of glioblastomas and promotes tumor formation and progression. However, attempts to treat glioblastoma with EGFR tyrosine kinase inhibitors have been unsuccessful thus far. The current standard of care is especially poor in patients with a constitutively active form of EGFR, EGFRvIII, which is associated with shorter survival time. This study examined the effect of GZ17-6.02, a novel anti-cancer agent undergoing phase 1 studies, on two EGFRvIII+ glioblastoma stem cells: D10-0171 and D317. In vitro analyses showed that GZ17-6.02 inhibited the growth of both D10-0171 and D317 cells with IC50 values of 24.84 and 28.28 µg/mL respectively. RNA sequencing and reverse phase protein array analyses revealed that GZ17-6.02 downregulates pathways primarily related to steroid synthesis and cell cycle progression. Interestingly, G17-6.02’s mechanism of action involves the downregulation of the recently identified glioblastoma super-enhancer genes WSCD1, EVOL2, and KLHDC8A. Finally, a subcutaneous xenograft model showed that GZ17-6.02 inhibits glioblastoma growth in vivo. We conclude that GZ17-6.02 is a promising combination drug effective at inhibiting the growth of a subset of glioblastomas and our data warrants further preclinical studies utilizing xenograft models to identify patients that may respond to this drug.

Verified
Journal Article
Open access
PDF file
ZBZachary A. Bordeaux
Zachary A. Bordeaux
SRSriya V. Reddy
Sriya V. Reddy
KLKevin Lee
Kevin Lee
WLWeiying Lu
Weiying Lu
JCJustin Choi
Justin Choi
MKMadan Kwatra
Madan Kwatra
Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL) and is characterized by epidermotrophism of malignant CD4+ T-lymphocytes. When MF advances to a recurrent stage, patients require treatment with systemic therapies such as vorinostat, a histone deacetylase inhibitor. While vorinostat has been shown to exhibit anti-tumor activity in MF, its exact molecular mechanism has yet to be fully discerned. In the present study, we examined the transcriptomic and proteomic profiles of vorinostat treatment in two MF cell lines, Myla 2059 and HH. We find that vorinostat downregulates CTLA-4, CXCR4, and CCR7 in both cell lines, but its effect on several key pathways differs between the two MF cell lines. For example, vorinostat upregulates CCL5, CCR5, and CXCL10 expression in Myla cells but downregulates CCL5 and CXCL10 expression in HH cells. Furthermore, vorinostat upregulates IFN-γ and IL-23 signaling and downregulates IL-6, IL-7, and IL-15 signaling in Myla cells but does not affect these pathways in HH cells. Although Myla and HH represent established MF cell lines, their distinct tumor origin from separate patients demonstrates that inherent phenotypic variations within the disease persist, underscoring the importance of using a variety of MF cells in the preclinical development of MF therapeutics.

31 October 2023 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
SBSarah L Barnett
Sarah L Barnett
Meghan Nicole MillerMeghan Nicole Miller
Meghan Nicole Miller
JAJacob M Appel
Jacob M Appel
JCJoshua Choe
Joshua Choe
SOSammy Othman
Sammy Othman
JBJames P Bradley
James P Bradley
Facial feminization surgery (FFS) is a form of gender-affirming care for the transgender population that is currently a highly debated topic both inside and outside of the medical community. Currently, a paucity of information is available in plastic surgery literature on ethical issues surrounding FFS. In this paper, we discuss 5 major ethical considerations for plastic surgeons with regard to FFS: (1) how society's changing view of gender has impacted the importance of FFS; (2) whether FFS is medically necessary and should be covered by insurance; (3) to what extent resources should be invested in removing barriers to access FFS; (4) how patient selection criteria should address the irreversibility of the procedure and age of consent; and (5) how femininity and beauty standards contribute to each other and whether they can be disentangled. This paper aims to analyze the arguments made for and against each of these 5 nuanced issues and to expand these debates from the theoretical to the practical by suggesting approaches for reconciliation.

26 May 2026 in Current Opinion in Ophthalmology
Verified
Journal Article
Closed access
Meghan Nicole MillerMeghan Nicole Miller
Meghan Nicole Miller
DHDavid Hsu
David Hsu
PTPrashant D. Tailor
Prashant D. Tailor
MSMatthew R. Starr
Matthew R. Starr
Purpose of review: Ophthalmology has emerged as the proving ground for medical artificial intelligence (AI) because of its imaging-centric workflows, standardized data acquisition, and well defined clinical endpoints. Recently, the field has started transitioning from narrowly trained, task-specific algorithms toward multimodal models that are trained on large datasets and can be adapted to many tasks. These models may integrate information from images, text, and clinical data and are increasingly trialed in real-world settings. This review examines recent advances and ongoing controversies in the use of AI as a basic science, translational, and clinical research tool in ophthalmology. Recent findings: Recent literature highlights the growing role of self-supervised and foundation models for scalable phenotyping, biomarker discovery, and cross-task generalization, particularly in retinal imaging and optical coherence tomography (OCT). In parallel, large-scale clinical deployments, including cloud-based OCT platforms and autonomous diabetic retinopathy screening, demonstrate clinical impact while revealing persistent challenges related to workflow integration and patient generalizability. Regulatory and ethics-focused studies underscore increasing attention to validation rigor, bias, and postdeployment monitoring, exposing heterogeneity in research standards and physician practices. Summary: Ophthalmic AI is maturing toward real-world clinical implementation. Future progress will depend less on performance gains alone and more on clinical alignment, rigorous validation, equity-aware evaluation, and postdeployment surveillance, alongside continued investment in basic science to advance disease understanding and inform robust, generalizable model development.

Verified
Journal Article
Open access
PDF file
Meghan Nicole MillerMeghan Nicole Miller
Meghan Nicole Miller
DLDerrick Lin
Derrick Lin
SRSamantha Rabinovich
Samantha Rabinovich
GAGraysen Airth
Graysen Airth
SRSabrina Rainsbury-Silva
Sabrina Rainsbury-Silva
JLJustine C. Lee
Justine C. Lee
Facial gender-affirming surgery (FGAS) is a transformative step for transgender individuals in their gender care journey. Even so, the way outcomes are measured and reported is highly inconsistent and unstudied. This limits the ability to compare studies or develop clear, patient-centered benchmarks for success. We systematically assess how current research defines FGAS outcomes and lay the groundwork for a unified Core Outcome Set (COS). A systematic review was conducted following the PRISMA 2020 guidelines. PubMed was searched up to 15 March 2025; we identified 334 studies, and four reviewers independently screened the studies. After screening, 207 studies met the inclusion criteria, encompassing 30,937 patients. Data on study characteristics, surgical procedures, outcome domains, measurement tools, and follow-up duration were extracted. Descriptive statistics and chi-square analyses were used to evaluate reporting trends. Most studies emphasized aesthetic outcomes (60.56%) and complications (62.44%); fewer addressed psychosocial well-being (43.19%), quality of life (35.21%), or reoperation rates (21.60%). Only 26 of the 207 studies used validated outcome instruments, such as FACE-Q or PROMIS (p < 0.001). Among studies that reported satisfaction, only 41.2% provided numerical or stratified scores. Outcome reporting in FGAS research is fragmented and dominated by subjective or unvalidated assessments. A standardized COS is needed to unify research practices, facilitate meaningful comparisons, and ensure that outcomes align with patient-defined measures of surgical success.

20 May 2024 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
PDF file
EAElisa Atamian
Elisa Atamian
SOSammy Othman
Sammy Othman
JCJoshua Choe
Joshua Choe
Meghan Nicole MillerMeghan Nicole Miller
Meghan Nicole Miller
JBJames Bradley
James Bradley
Background: Granulomatosis with polyangiitis (Wegener’s granulomatosis) causes progressive nasal collapse, nasal obstruction, and central face deformity. It is not known whether cartilaginous nasal reconstruction should be performed immediately or delayed until after disease “burnout.” Objectives: The aims of this research regarding nasal collapse due to Wegener’s granulomatosis were to (1) assess the functional and aesthetic outcomes following immediate vs delayed nasal reconstruction; and (2) measure the impact of psychosocial well-being (anxiety, depression, social isolation) in immediate vs delayed nasal reconstruction. Methods: Wegener’s patients with either immediate or delayed nasal surgery (n = 61) were compared. Functional and aesthetic severity were compared with the validated Standard Cosmesis and Health Nasal Outcome Survey (SCHNOS) score (t test). In addition, Patient-Reported Outcomes Measurement Information System (PROMIS) perioperative and 1-year follow-up surveys were analyzed. Results: At initial consultation, SCHNOS score severity types were similar for both groups (immediate vs delayed): mild 15% vs 15%; moderate 59% vs 60%, and severe 26% vs 25%. Over a 30 ± 4 month period, delayed surgery patients’ conditions deteriorated, with a shift from mild to more severe SCHNOS scores, from 25% severe at initial consultation to 85% before surgery. PROMIS scores at presentation were high compared to the general public; by the time of delayed surgery, patients had significantly worsened: anxiety from 28 to 73; depression from 18 to 62; and social isolation from 20 to 80. Although both immediate and delayed groups improved after surgery in functional and psychosocial scores, the immediate surgery group’s improvement was superior. Conclusions: Data showed superior functional and aesthetic scores and superior psychosocial indicators with immediate cartilaginous nasal reconstruction, compared with waiting until disease burnout to undergo surgery. Level of Evidence: 4: